Skip to content

Efficacy of dobutamine infusion for exclusion of left atrial appendage thrombus

Efficacy and safety of dobutamine infusion for exclusion of left atrial appendage thrombus in patients with severe spontaneous echo contrast caused by atrial fibrillation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031220544
Enrollment
20
Registered
2022-12-27
Start date
2023-01-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation Atrial fibrillation

Interventions

Dobutamine injection 5-20 microgram / kg / min intravenously for up to 10 minutes

Sponsors

Machino Tomoko
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria for the first step 1)Patients with valvular or non-valvular atrial fibrillation (AF) 2)Patients undergoing transesophageal echocardiography (TEE) for evaluation of intracardiac thrombus before catheter ablation for AF, percutaneous left atrial appendage (LAA) occlusion, percutaneous mitral valve commissurotomy, and electrical cardioversion, or patients suspected cardiogenic stroke and undergoing TEE to evaluate intracardiac thrombus 3)Patients with a CHADS2 score of 1 or higher 4)Patients receiving anticoagulant therapy 5)Men and women over 20 years old 6)Patients with written informed consent Inclusion criteria for the second step 7)Patients with severe blood flow stasis (spontaneous echo contrast grade of 3 or 4) in left atrium (LA) and LAA

Exclusion criteria

Exclusion criteria: Exclusion criteria for the first step 1) Patients with past history of LAA occlusion or resection 2) Patients with systolic blood pressure of 80 mmHg or less or 180 mmHg or more before the start of TEE 3) Patients with heart rate (measured by the average method) of 100 bpm or more before the start of TEE 4) Patients receiving catecholamines 5) Patients with a history of allergic reactions to dobutamine 6) Patients with hypertrophic cardiomyopathy who have intraventricular obstruction with a maximum pressure gradient of 30 mmHg or more 7) Patients with unstable angina 8) Patients with disorientation, quadriplegia, dysarthria, and visual field impairment 9) Women who are pregnant or may become pregnant 10) Patients who are judged inappropriate by the researcher Exclusion criteria for the second step 11) Patients with obvious LAA thrombus without infusion of dobutamine 12) Patients with systolic blood pressure of 80 mmHg or less or 180 mmHg or more before the start of dobutamine infusion 13) Patients with heart rate (measured by the average method) of 100 bpm or more before the start of dobutamine infusion

Design outcomes

Primary

MeasureTime frame
Changes in the grade of spontaneous echo contrast in LA and LAA before and after dobutamine infusion evaluated by the doctor performed TEE

Secondary

MeasureTime frame
Changes in the grade of spontaneous echo contrast in LA and LAA before and after isoprenaline infusion evaluated by other independent investigator Changes in the LAA blood flow velocity, LAA wall motion velocity, LAA emptying fraction, left ventricular ejection fraction before and after isoprenaline infusion Number of cases for which the presence or absence of LAA thrombus could be diagnosed after isoprenaline infusion, and prevalence of LAA thrombus

Contacts

Public ContactTomoko Machino

University of Tsukuba

tomoko-machino@md.tsukuba.ac.jp+81-29-853-3143

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026